QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: PSUR Single Assessment and EU Procedures

Test your understanding of the concepts covered by GVP Module VII: PSUR Single Assessment and EU Procedures.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A new indication is authorised six months after a PSUSA conclusion. What is the most appropriate implication for the MAH?

The previous PSUSA conclusion automatically covers all future populations The new indication may alter exposure, clinical context and benefit-risk considerations, requiring reassessment of relevant PV and regulatory impacts The new indication is relevant only to commercial planning, not pharmacovigilance The MAH should ignore the previous PSUSA in all future reporting

Question 2 of 10 Why should a company maintain an accurate record of the relevant assessor and procedural roles for each PSUSA rather than rely on historical assumptions?

Because assessor roles and regulatory arrangements may differ by procedure and change over time Because the assessor becomes the legal MAH during the procedure Because previous PSURs are invalid if the assessor changes Because only historical procedural information is accepted in a PSUR

Question 3 of 10 Which issue is most characteristic of validation or procedural completeness rather than substantive scientific assessment?

Whether a newly observed event changes the benefit-risk balance Whether risk-minimisation measures are effective Whether the correct reporting interval, DLP, format and required documents were submitted Whether the clinical importance of a signal differs by indication

Question 4 of 10 What is the most significant governance risk when Regulatory Affairs considers a PSUSA action complete but Pharmacovigilance considers it open?

The organisation may have inconsistent cross-functional understanding of requirements, ownership, deadlines and completion criteria The PSUR must automatically be withdrawn The active substance must be removed from the EURD framework The disagreement proves that the scientific assessment was invalid

Question 5 of 10 Which sequence best represents the general PSUSA lifecycle described in the article?

Implementation, PSUR preparation, validation, assessment, reporting obligation Reporting obligation, PSUR preparation and submission, validation, scientific assessment, regulatory conclusion and implementation PRAC recommendation, product launch, PSUR preparation, MAH approval and inspection PSUR preparation, automatic acceptance, RMP closure, product withdrawal and follow-up

Question 6 of 10 After a change in MAH, which information is most important for pharmacovigilance and regulatory continuity?

Only the commercial transfer agreement Only the most recent PSUR submission receipt PSUR and PSUSA history, open commitments, safety concerns, RMP status, product-information changes and outstanding actions Only the previous MAH’s organisational chart

Question 7 of 10 How should a significant non-EU regulatory action concerning the same safety issue generally be handled in the EU PSUR process?

It should automatically determine the EU regulatory outcome It should be ignored because only EU evidence is relevant Its underlying evidence and rationale should be evaluated as potentially relevant safety information, while the EU framework remains governing It should replace the PSUSA assessment if the foreign authority acted first

Question 8 of 10 Which statement best captures the relationship between coordinated assessment and product-level implementation?

A coordinated EU assessment means that one implementation action always covers every product Coordinated assessment promotes consistency, but each MAH must determine and document how the outcome applies to its own authorisations Implementation is performed only by PRAC because it issued the scientific recommendation Product-level implementation is unnecessary when products share an active substance

Question 9 of 10 Why should an MAH not simply copy another MAH’s safety conclusion for a product containing the same active substance?

Because shared evidence is never relevant to more than one product Because each MAH must assess how common evidence applies to its own products, indications and populations Because only the regulator is permitted to read another MAH’s conclusion Because all MAHs are legally required to reach different conclusions

Question 10 of 10 A PSUSA outcome requires a change to product information for several products. What should the MAH do first when planning implementation?

Assume that one generic change applies identically to all products Map the outcome against each affected product’s authorisation, wording and applicable regulatory procedure Wait until the next PSUR to determine which products are affected Ask another MAH to implement the change for the entire active substance

Knowledge Assessment: PSUR Single Assessment and EU Procedures

Cookie Settings